Trial
NCT05436990
Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Yonsei University
Collaborators
—
Condition
Acral Melanoma
Intervention
Pembrolizumab, Vactosertib
Why stopped
According to the protocol criteria, during the Phase 1 analysis, the registered participants' imaging evaluation responses did not meet the criteria, leading to an early termination
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-02